NEW YORK, NY--(Marketwired - Jun 6, 2013) - Plandaí Biotechnology, Inc. (
Plandaí Biotechnology, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, plans to enter into Phase II human clinical trials using Phytofare™ with the eventual goal being FDA approval of an antimalarial drug. The recently announced results of the study will go a long way to getting Plandaí one step closer to submitting its application to the U.S. Food and Drug Administration requesting those human trials.
The study, conducted under the supervision of Dr. Sanjeev Krishna, a professor of molecular parasitology and medicine at St George's London School of Medicine, showed proof in analytical tests that Plandaí's Phytofare™ Catechin Complex was effective in killing the malaria parasite, plasmodium falciparum. Dr. Krishna developed the tests that were conducted at St George's London School of Medicine at the Division of Cellular and Molecular Medicine, Centre for Infection.
In the study, the most dominant catechin, Epigallocatechin Gallate (EGCG) was isolated from Plandaí's Phytofare™ extract and then had its effectiveness in killing the P. falciparum parasite compared against a purified EGCG extract.
Continue Reading to learn more about Plandai's trial results at www.stockmarketmediagroup.com/features.
About Stock Market Media Group
Stock Market Media Group, formerly Stock House Group, is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the media with its Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research on its website for Investors to become better informed on small cap stocks. For more information www.stockmarketmediagroup.com.